UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-42749
POMDOCTOR LIMITED
(Exact name of registrant as specified in its charter)
Yongxu Industrial Park No. 19-23 Hejing Road
Dongsha Street, Liwan District
Guangzhou 510000
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
On October 28, 2026, POMDOCTOR LIMITED (the “Company”)
received two letters (the “Letters”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock
Market LLC (“Nasdaq”) regarding deficiencies with respect to certain continued listing requirements of The Nasdaq Global Market.
The first Letter notified the Company that, based upon the Company’s
MVLS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no longer meets the requirement
under Nasdaq Listing Rule 5450(b)(2)(A) to maintain market value of listed securities (“MVLS”) of at least $50 million (the
“MVLS Requirement”). The Staff also noted that the Company does not meet the requirements under Nasdaq Listing Rule 5450(b)(3)(A).
Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance
period of 180 calendar days, or until April 26, 2027, to regain compliance with the MVLS Requirement. If at any time during the compliance
period the Company’s MVLS closes at $50 million or more for a minimum of ten consecutive business days, Nasdaq will provide the
Company with written confirmation of compliance and the matter will be closed.
The second Letter notified the Company that, based upon the Company’s
MVPHS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no longer meets the requirement
under Nasdaq Listing Rule 5450(b)(2&3)(C) to maintain a minimum market value of publicly held shares (“MVPHS”) of $15
million (the “MVPHS Requirement”).
Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), the Company has a compliance
period of 180 calendar days, or until April 26, 2027, to regain compliance with the MVPHS Requirement. If at any time during the compliance
period the Company’s MVPHS closes at $15 million or more for a minimum of ten consecutive business days, Nasdaq will provide the
Company with written confirmation of compliance and the matter will be closed.
If the Company does not regain compliance prior to the expiration of
the applicable compliance period, the Company will receive written notification that its securities are subject to delisting. At that
time, the Company may appeal the delisting determination to a Hearings Panel.
The Company intends to monitor its MVLS and MVPHS and evaluate available
options to regain compliance with the applicable continued listing requirements within the compliance period.
There can be no assurance that the Company will regain compliance with
the applicable Nasdaq continued listing requirements within the compliance period or otherwise maintain compliance with Nasdaq’s
other continued listing requirements.
On November 2, 2026, the Company issued a press release regarding its
receipt of the Letters. A copy of the press release is furnished as Exhibit 99.1 to this Report on Form 6-K.
The information contained in this Report on Form 6-K, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing
of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference
in such filing.
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated November 2, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
POMDOCTOR LIMITED |
| |
|
|
| |
By: |
/s/ Zhenyang Shi |
| |
Name: |
Zhenyang Shi |
| |
Title: |
Chairman and Chief Executive Officer |
| |
Date: |
November 2, 2026 |
Exhibit
99.1
POMDOCTOR
LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
GUANGZHOU,
China, November 2, 2026 /PRNewswire/ — POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (Nasdaq: POM), a digital
healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that
on October 28, 2026, it received two letters (the “Letters”) from the Listing Qualifications Department (the “Staff”)
of The Nasdaq Stock Market LLC (“Nasdaq”) regarding deficiencies with respect to certain continued listing requirements of
The Nasdaq Global Market.
The
first Letter notified the Company that, based upon the Company’s MVLS for the 30 consecutive business days from September 16, 2026
through October 27, 2026, the Company no longer meets the requirement under Nasdaq Listing Rule 5450(b)(2)(A) to maintain market value
of listed securities (“MVLS”) of at least $50 million (the “MVLS Requirement”). The Staff also noted that the
Company does not meet the requirements under Nasdaq Listing Rule 5450(b)(3)(A).
Pursuant
to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until April 26, 2027, to regain compliance
with the MVLS Requirement. If at any time during the compliance period the Company’s MVLS closes at $50 million or more for a minimum
of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and the matter will be closed.
The
second Letter notified the Company that, based upon the Company’s MVPHS for the 30 consecutive business days from September 16,
2026 through October 27, 2026, the Company no longer meets the requirement under Nasdaq Listing Rule 5450(b)(2&3)(C) to maintain
a minimum market value of publicly held shares (“MVPHS”) of $15 million (the “MVPHS Requirement”).
Pursuant
to Nasdaq Listing Rule 5810(c)(3)(D), the Company has a compliance period of 180 calendar days, or until April 26, 2027, to regain compliance
with the MVPHS Requirement. If at any time during the compliance period the Company’s MVPHS closes at $15 million or more for a
minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and the matter will
be closed.
If
the Company does not regain compliance prior to the expiration of the applicable compliance period, the Company will receive written
notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings
Panel.
The
Company intends to monitor its MVLS and MVPHS and evaluate available options to regain compliance with the applicable continued listing
requirements within the compliance period.
There
can be no assurance that the Company will regain compliance with the applicable Nasdaq continued listing requirements within the compliance
period or otherwise maintain compliance with Nasdaq’s other continued listing requirements.
About
POMDOCTOR LIMITED
POMDOCTOR
LIMITED (Nasdaq: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare
capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks
and real-world healthcare data to support more personalized, continuous and data-driven healthcare services.
Forward-Looking
Statements
This
press release contains forward-looking statements. These forward-looking statements include, without limitation, statements concerning
the Company’s ability and plans to regain and maintain compliance with Nasdaq’s continued listing requirements, including
the MVLS Requirement and the MVPHS Requirement, the Company’s evaluation of alternatives available to regain compliance, and the
continued listing of the Company’s Class A ordinary shares on Nasdaq.
Forward-looking
statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such statements.
Factors that could cause actual results to differ materially include, among others, the Company’s ability to regain and maintain
compliance with the MVLS Requirement, the MVPHS Requirement and other Nasdaq continued listing requirements, fluctuations in the market
price of the Company’s Class A ordinary shares, and the other risks and uncertainties described in the Company’s filings
with the U.S. Securities and Exchange Commission.
The
Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date
of this press release, except as required by applicable law.
Investor
Relations Contact
POMDOCTOR
LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent
Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
